Erlotinib Recruiting Phase 3 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02714010EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC